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Sustained fetal tachyarrhythmias ay cause fetal bydrops and 
may lead to fetal death (I). Successful restoration of sinus 
rhythm or more acceptable heart rates by a~m~~~stratio~ of 
a~t~arrhyt~m~c drugs to the mother or, more recently, directly 
to the fetus is described in many reports (2-Q 
Maternal administration of digoxin has traditionally been 
of choice in the earlier years of fetal therapy (2), 
tiestiorms have since been raised about he effec- 
tiveness of this drug, especially in hydropic feetuses, a variety of 
newer drugs and other methods have also been applied to treat 
fetal tachycardia (9-15). Because the numher of patients with 
this condition is limited, the optimal method of management 
and the drugs to use are still a matter of controversy. We 
present a multicenter etrospective study of the in utero 
management, fetal outcome and neonatal follow-up of patients 
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with fetal tachycardia, with emphasis on supraventricular 
tachycardia and atria1 flutter. 
S 
~tkwts. This retrospective study included 51 feral patients 
seen because of tacbycardia at the fetal cardiology centers of 
the University of Maryland Hospital (Baltimore), Yale New 
Haven Hospital (New Haven) and the University Hospital 
Utrecht (Utrl;cirt, The Netherlands) from 1985 to 1992. The 
following variables were sought in the charts of these patients: 
gestational ge at recognition of the tachycardia, heart rate, 
mechanism of the tachycardia as noted on prenatal M-mode 
echocardiography and postnatal electrocardiography, t e pres- 
ence of fetal hydrops, therapy in utero and its result, gcsta- 
tlonal age at birth, mode ofdelivery, Apgar score and postnatal 
therapy. The patients were usutlly referred for evaluation of 
tachyarrhythmia, which was noted during routine prenatal 
visits. The mechanism of tachycardia was determined by 
M-mode echocardiographic analysis of the relation between 
atrial and ventricular contraction. 
For the purpose of this study, sqraw~e,ztricular rochycardia 
was &fined by a I:1 aIrioventricular (AV) conduction reelation 
with a rate of >I80 beatsjmin, with little beat-to-beat variation, 
often with sudden onset and cessation of the tachycardia. 
,&tial@tterwas defined as a regular atrial rate of 400 to SO0 
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bea:Hts/min with fixed or variable AV block resulting ina lower 
ventricular rate and occasional irregular ventricular response. 
Ventricular tachycardia was characterized by dissociated 
atrial and ventricular rhythms in which the atrial rate was 
slower than the ventricular rate (16). 
Fetuses were considered tobe hydropic if one or more of 
the following symptoms of cardiac failure were detected: 
pericardial effusion, pleural effusion, ascites or skin edema. 
The highest fetal heart rate (peak fetal hearr ate) was 
noted to give an indication of the severity of the tachycardia. 
Srutkrical evuluarion of the differences in heart rates and 
time to successful conversion was performed by Student I test. 
Figure 1 shows the 51 allocated b three groups 
with dil&rcnt mechanisms of tachycardia: atria1 flutter, su- 
~~~nt~~lar tachycardia and ventricular tachycardia. One 
fetus had one episode of supraventricular tachycardia and one 
of atrial f utter and is counted as two patients. One hydropic 
fetus with atrial flutter (ventricular rate 260 beats/min), hy- 
popIasia ofthe left ventricle and dilation of the left atrium died 
immediately postnataliy. 
In the group of 34 patients with supraventricular tachycar- 
dia fetal hydrops was seen in 16. Of the 16 patients with atrial 
flutter, 6had fetal hydrops. The two fetuses with ventricular 
tachycardia d not develop hydrops and returned to normal 
sinus rhythm spontaneously; they were monitored until birth. 
One of these two had a relapse after birth and required 
medication for 6 months. 
In utero meat. Of the SO patients with either 
supraventricular tachycardia or atrial flutter, 34 were treated 
with maternal dministration of antiarrhythmic drugs (Fig. 2). 
The drug of first choice for initial therapy inthese patients was 
digoxin (n = 24) or flecainide (n = 10). Sixteen fetuses did not 
ure 1. Allocation ofpatients othe three study 
ups. AF = atria! flutter; Early = at time of 
recognition; FH = fetal hydrops: GA. = average 
gestational a eeksk Late = developed during 
treatment; p = average peak fetal 
(~at~m~n); = supraventrieular t 
= ve~t~i~~~~~ a~~~ycardia. 
receive drugs but were monitored until birth OF were delivered 
electively. 
No drug t~e~~~y. In 1 
used. In four fetuses 
during labor, so maternal 
Five patients with ta 
tored until birth. These feetuses bad only short bursts of 
ydropic at the tim 
m~~irnal signs of 
e three was eleciiv 
cesarian section after 3 days. All five survived. 
In five further patients, elective delivery was performed 
immediately after recognitio f the tachycardia, n three 
because the fetuses were at t aad in two (gestational ages 
33 and 34 weeks) because y were among the earliest 
subjects of this study, when elective premature delivery was
thought to be a good option, and fetal therapy was not widely 
used. 
One fetus was delivered by emergency esarian section 
when the tachycardia abruptly changed into a bradycardia of 
50 beats/min spontaneously. 
In the patient with hypoplasia of the left ventricle, maternal 
preeclampsia required induction of labor at 29 weeks of 
gestational age, after which the baby died of heart failure. 
Mafemol dncg therapy: nonhydropic fetuses. In the drug- 
treated group (Fig. 2), 19 fetuses were not hydropic (14 had 
supraventricular tachycardia; 5 had atrial flutter). These fe- 
tuses were initially treated by maternally administered digoxin 
(intravenous loading dosage of1.5 mglday, given in three parts, 
followed by an oral maintenance of 0.5 to 0.75 mg/day) (n = 
14) or flecainide (twice aday 100 to 150 mg o = 5). In 
the four fetuses with unsuccessful d~g~~~ tr rhythm 
control was achieved in one after addition of verapamil. In the 
remaining three fetuses, no rhythm control was achieved 
before birth. One of these fetuses was switched topropranolol 
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dose and maternal level. Another was controlle 
rt period but bad s~praveatric~~ar tacbyca 
a cesarian section was 
third was delivered by cesarian section (at 35 weeks) after 3 
days of unsuccessful digoxin therapy. 
In the group of nonhydropic fetuses with maternal drug 
therapy, 84% were successfully c verted, at least emporarily, 
to normal sinus rhythm. The m n number of drugs used in
each case to achieve acceptable rhythm control was one, and 
the median number of days required was 3 (Table 1). No 
fetuses died; one fetus returned to normal sinus rhythm during 
digoxin treatment but developed bradycardia~ t which time 
delivery was induced. 
Of nine fetuses with unsuccessful digoxin treatment, rhythm 
control was achieved in seven after the addition of other drugs. 
In three fetuses verapamil was added; in one fetus quinidine, in 
two fetuses two additional drugs (procainamide + flecainide 
and procainamide + verapamil) and in one fetus four addi- 
Hydropic fetuses. Fifteen of the 34 drug-treated fetuses 
were hydropic (11 had supraventricular tacbycardia; 4 bad 
atria1 flutter). These patients were initially treated with mater- 
nal administration of digoxin (n = 10) or flecainide (n = 5). 
Table 1. Results in the Drug-Treated Group 
No Hydr ps 
(II = 19) 
Acceptable rhythm control 84% 
Median no. of drugs 1(1-Z) 
Median no. of days 3 (1-14) 
Numbers in parentheses are ranges. 
Hydrops 
(II = 15) 
80% 
2(1-5) 
12.5 (3-70) 
~~~~~e 2. Maternal drug therapy according to the presence or absence 
ops and digoxin versus Oecainide. add. = additional; pat = 
tional drugs (q~~~idi~e, v rapamil, ~~o~a~~amide, 
lo!). In 2 of 10 fetuses with digox~~ as the initial dr 
control was not achieved before birth: one baby was delivered 
by cesarian section after 1 day of unsuccessful digoxin therapy 
eeks), and one fetus (at 33 weeks) died in utero after 
of unsuccessful digoxin therapy. Autopsy was not 
%n the three fetuses with ~~s~~cessf~~ hecainide treatment, 
rh~bm control was achieved in two, with the addition of 
digo~i~. E[n one patient with atrial flutter, rhythm control was 
not achieved before birth. In this case digoxin was added 
without resnlt, followed by pro~ai~amide, maternally and 
directly to the fetus (intraumbilical), also without success. The 
ition of the fetus deteriorated, and after spontaneous 
rupture of the membranes a cesarean section was performed at 
30 weeks. 
In this group of hydropic fetuses, 80% were successfully 
converted to normal sinus rhythm with maternal drug therapy. 
The median number of drugs used in each case to achieve 
acceptable rhythm control was two, and the median umber of 
days required was 12.5 (Table 1). 
In this drug-treated group, two hydropic patients died, one 
in utero after 3 days of unsuccessful digoxin therapy, and the 
other, who was uccessfully converted to normal sinus rhylhm 
with digoxin but was still hydropic after 1 week, was electively 
delivered by cesarean section because of a poor biophysic 
profile and died in the delivery room. 
Maternal digoxin levels were obtained in 34 mothers and 
varied from 0.6 to 2.3 ng/ml (therapeutic range 0.5 to 
2.0 @ml). 
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lm Bm ly 1 *By 3Y ag 
3. Drug hwpy af’ter birth iii the 22 patients with SM~~~V~~- 
&&yc&ii~ @VT* [mechanism unspxiticd; ,whably aEOil- 
Ahmat ndvetxe e&us. lin the four cases in which procain- 
amide was used, three mothers complained of nausea and 
vomiting. Two of the 15 mothers receiving flecainide had 
blurred vision and dizziness that resolved after the dos 
decreased. 
S~p~v~Mrictrlnr tachycardia wrs~~s alrid jhlter With re- 
gard to the different mechanisms of tachycardia in the same 
patient group, accept&!e rhythm control was f 
the 3 drug-treated patients with supraventri 
(in 10 of I9 hydropic turd I2 of 14 nonhyd E 
nine drug-treated fetuses with atrial flutter. normal sinus 
rhythm was achieved in six (in four of live ~onhydropic and iu 
two of four hydropic fetu.scs). fn three patients with atrial 
flutter, no conversion to sinus rhythm was obtained, and 
despite the occasiona occurrcncc of an increase of AV block, 
resulting in a lower ventricular rate, no improvement in the 
fetal clinical condition could be substantiated. Therefore, drug 
therapy was effective in 66% of the atrial tlutters and in 88% 
ycardias. 
nutcome after birth. At birth the rhythm 
status WBS as follows (n = 48): 50% of all surviving patients had 
a relapse of tachycardia after birth (64% of the patients with 
fetal atrial 9Iutter and 44% of the patients with fetal supraven- 
tricular tachycardia). In the group of patients with supraven- 
tricular tachycardia. u reentry mechanism could be seen on the 
~9~ctr~~~rdi~~~r~~rn in eight (four Wolff-Parkinson-White syn- 
drome, of whom two had no more tachycardia after birth; four 
permanent junctional reciprocating tachycardias). in nine pa- 
tients reentry mechanisms were considered because fet,l echo- 
c=diogtzphic findings suggested a possible underlying reentry 
mechanism causing the tachycardia, but postnatal electrocar- 
diography could not confirm this. These patients received 
prophylactic antiarrhythmic drug treatment. Patients who had 
tachycardia at birth were converted to normal sinus rhythm fry 
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provocation of the vagal diving reflex (two patients, bot 
unsuccessful), cardioversion 
transvenous atrial overdrive 
cessful) or antiarr~yt~~ic d 
ously mentioned meth 
At the age of 1 the patiemts with a history of 
fetal supraventricular f zhycardia or atrial gutter were rceeiv- 
ing antiarrh~~~ic drugs (dig 
with ~ro~ranolol, v~r~~a~t~ or 
study and the mechanisl~~ of thei 
with pc~flla~c~~t j~~cti~)~a9 rcci 
group of 22 were still reccivi 
3 years. 
tre~t~~e~t teak be indi- 
ardia and that ~~duccd 
quately (res~ctively, SO% 4% col~versio~) by mater~a9 
drugs. a9tbo~~h the patients 
precluded. The hydropic fetuses were found to have a rignifi- 
cantly higher peak fetai heart rate than the nonhydrtipic 
249 vs. 231 beats~m~n, p = 0.02). 
A comparison of supraventric- 
utter shows that drug therapy was 
successful in restoring acceptable rhythm control in 88% of the 
fetuses with supraventricular tachycardia and in 66% of those 
with atria9 flutter. 
Ckoicl! of d Digoxin and hecainide were the drugs of 
first choice in t udy. Other drugs used in addition included 
verapamil, the use of which was stopped after 198’7 after 
studies that showed adverse effects of verapamil on myocardial 
function in neonates with congestive heart failure (18). Mater- 
nal adverse effects caused by procainamide and flecainide were 
mild and transient. The use of flecainide is still controversial 
because of a reported fetal demise (5) and potential maternal 
risk (19). We have continued the use of flecainide in this 
setting because of the observation that flecainide appears to be 
more effective than digoxin in our series, although with the 
limited numbers there is no stat~st~ca99y signi 
Although we did not evaluate ventricular function in our 
study, we suggest in agreement with the previousiy mentioned 
study (19) and with Fish et al. (20) the use of the commonly 
accepted excfusion criteria for mother and child, induding poor 
JACC Vol. 24. No. 5 
November 1, 1994:1341-J 
te toward the use 
tachycardia in our group. e realize that he treatment of fetal 
tachycardia retmains a diligent 
peutic approaches may lead to 
nd extend our ~~dersta~d~~g of this prob- 
further cooperative prospective nvestiga- 
tions are necessary to create an effective photoed. 
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